Cenobamate Shows Stronger Real-World Seizure Control - Takeaways - MDSpire

Cenobamate Shows Stronger Real-World Seizure Control

Large retrospective analysis highlights differences in seizure control, retention, and adverse effects among newer agents

  • By

  • Henry Thomas

  • March 4, 2026

  • 2 min

Share

  • 1

    Cenobamate demonstrated superior seizure response and freedom compared to brivaracetam, lacosamide, and perampanel in drug-resistant focal epilepsy patients.

  • 2

    The CREW study analyzed data from nearly 2,000 patients across 71 epilepsy centers, focusing on newer antiseizure medications.

  • 3

    Adjusted models showed cenobamate significantly increased the odds of achieving a 50% reduction in seizure frequency at 6 and 12 months.

  • 4

    Cenobamate had the highest incidence of adverse effects, yet this did not negatively impact long-term treatment retention.

  • 5

    The study highlights the need for prospective trials to better inform treatment sequencing in focal epilepsy management.

Original Source(s)

Cenobamate Shows Stronger Real-World Seizure Control

  • by Henry Thomas

  • March 4, 2026

Related Content

Case Report: Epileptic phenotype in a patient with a MARK2 variant: the first detailed description and review of the literature

Acupuncture for Neuroinfections?

A recent Perspective offered a speculative mechanistic argument for acupuncture’s potential role as an adjunctive strategy in neuroinfectious diseases.

Tenecteplase Fails to Boost EVT Outcomes

Phase 3 stroke trial leaves open the possibility of clinically meaningful benefit or harm in selected late-window patients.